Why inside-knee pain without swelling is the right moment to act

That ache on the inside of the knee — present on stairs, noticeable after sitting, occasionally catching as you walk — without any obvious swelling or warmth, is not a minor complaint to monitor indefinitely. It is, in clinical terms, the footprint of early articular cartilage damage, and it marks a window that closes as the disease progresses.

The absence of swelling is clinically significant. Articular cartilage has no direct blood supply and no nerve fibres running through it; the inflammatory response that produces visible joint effusion simply cannot originate at the cartilage surface itself. What early Grade 1–2 lesions in the medial compartment do produce, as pressure and friction accumulate, is localised mechanical pain, catching sensations, and reduced ease of movement — but no puffiness, no warmth. Just a persistent inside-knee ache that patients often attribute to muscle tightness or the vague onset of 'wear and tear'.

Untreated lesions larger than approximately 1 cm carry a recognised tendency to worsen over time and progress toward full-thickness cartilage loss and osteoarthritis. Intervening before the joint reacts — before effusion and structural collapse become the clinical picture — is precisely when a protective collagen scaffold injection can coat and cushion damaged surfaces rather than attempt to rescue an end-stage joint. The symptom pattern that feels too mild to act on is, in practice, the optimal moment to seek assessment.

What early cartilage damage actually does — and why it rarely resolves alone

The problem with an untreated cartilage lesion is that it tends to enlarge through use. Without a protective surface, exposed subchondral bone creates a zone of concentrated mechanical stress during normal loading. Each movement — walking, descending stairs, rising from a chair — generates shear forces at the defect's edge, gradually undermining adjacent cartilage and widening the area of damage in a self-reinforcing cycle. A 5 mm lesion that causes intermittent catching on stairs does not simply stay a 5 mm lesion; the same forces that produced it continue acting on a surface that is now structurally compromised.

At the medial compartment, this mechanical dynamic is amplified. The inside of the knee bears a disproportionate share of body weight through the mid-stance phase of gait, meaning edge-loading around even a modest defect is substantial. When the cartilage immediately surrounding a lesion eventually softens and fragments, debris and altered joint chemistry can trigger a synovial reaction — producing the effusion and warmth that, by this stage, signal secondary involvement has already begun. The joint has moved from a focal mechanical problem to a broader inflammatory one.

The clinical implication of that sequence is that the period before surrounding cartilage and subchondral bone become part of the problem — rather than after — is when intervention has the most structural leverage. Early medial compartment damage does not hold its position; it either progresses or, with appropriate support, is given the conditions to stabilise.

How the ChondroFiller injection works

During an outpatient appointment, a two-component Type I collagen liquid is prepared and delivered directly into the knee joint under real-time ultrasound guidance — no incisions, no theatre admission, no anaesthetic. The formulation is acid-extracted and highly viscous; once placed at the damaged cartilage surface it polymerises rapidly in situ, setting as a collagen scaffold that coats the load-bearing areas of the joint in a single session. From the patient's perspective, the appointment is straightforward: the joint is imaged, the material is placed precisely at the area of damage, and the scaffold begins to gel before the appointment ends.

The biological mechanism is acellular matrix-induced chondrogenesis. ChondroFiller® itself contains no donor or laboratory-grown cells; instead, the collagen scaffold creates conditions that recruit the patient's own progenitor cells from the surrounding synovium and subchondral bone. A 2025 ex vivo osteochondral study confirmed this recruitment effect directly, recording a 2.4-fold increase in DNA content within the scaffold by day 14 — active cellular ingrowth without any exogenous cell delivery. At the same time, the physical presence of the scaffold acts as a top-down cushion over the worn surface, reducing bone-on-bone friction while the repair process develops beneath it. The injection therefore supports the body's own repair processes through two complementary routes: mechanical protection at the surface and biological signalling that draws in the cells needed for longer-term tissue remodelling.

Who is suitable — and how the damage is confirmed at the right stage

Patients presenting with the early inside-knee pain pattern described — mechanical aching on the medial side, catching without warmth or effusion — occupy precisely the clinical window where ChondroFiller injection tends to perform best. Grade 1–2 cartilage lesions with intact surrounding joint architecture are the target: the scaffold has a structurally sound environment to work in, and progression toward full-thickness loss has not yet compressed the joint space or altered its mechanics.

Unlike cell-based surgical procedures, which carry specific defect-size requirements and are sometimes restricted by patient age, ChondroFiller carries no upper age limit and no defect-size restriction. A 55-year-old with a modest patch of softening and a 70-year-old with more widespread early-stage thinning can both be assessed on the same basis — suitability turns on damage stage and remaining joint architecture, not age or defect geometry.

The practical question is how to confirm damage stage before the joint reaches the effusion-producing threshold. Standard X-ray and even routine MRI can miss the biochemical changes that precede structural breakdown. Advanced cartilage MRI sequences — T2 mapping and dGEMRIC — detect alterations in water content and glycosaminoglycan concentration at the compositional level, identifying cartilage softening before full-thickness loss becomes visible on standard imaging. This is the diagnostic route that enables intervention at the pre-swelling stage.

Absence of swelling and warmth at presentation should be read as a positive indicator for early-stage assessment, not a reason to defer investigation. Where ChondroFiller is less appropriate is in joints where significant space narrowing has already occurred: established osteoarthritis confirmed on imaging is associated with substantially poorer outcomes. A specialist assessment is needed to determine where on that continuum an individual patient sits.

What the clinical evidence shows

Three clinical datasets, spanning the knee, wrist, and hip, currently underpin ChondroFiller's evidence base — each contributing something the others cannot.

The oldest and most controlled entry point is the first multicentre randomised controlled trial, published in 2016 (n=23). IKDC scores improved significantly from baseline at both 3 and 6 months (p<0.05), and those gains held at 12 months. Serial MRI confirmed the trajectory: defects filled well immediately after injection, and cartilage quality on MOCART scoring continued to mature progressively over the full 52-week follow-up. No adverse events were recorded. A 2024 prospective knee series (n=17, mean age 31) replicated the functional improvements on both the Lysholm and IKDC scales at 3, 6, and 12 months (p<0.05). Notably, scores between 6 and 12 months were not statistically different from one another — suggesting the benefit is consolidated by the mid-year mark rather than continuing to accumulate indefinitely.

The sharpest comparative evidence comes from a 2025 wrist RCT, which offered the rare advantage of second-look arthroscopy. ChondroFiller-treated defects achieved a median Outerbridge score of 1.5 versus 3 in controls (p=0.006), and an ICRS grade of 1 versus 3 (p=0.002) — a meaningful difference in cartilage quality confirmed visually at follow-up. The long-term hip cohort, covering 12 to 60 months and already referenced in the candidacy discussion above, adds durability to the early-stage picture.

The limitations are worth naming plainly. Study cohorts across all of these datasets are small. No large-scale randomised trial has been conducted specifically in the medial knee compartment. There is no published head-to-head comparison between ChondroFiller and other injectables — PRP or hyaluronic acid — in patients with early-stage cartilage damage. The evidence available is encouraging on its own terms; it does not yet resolve how ChondroFiller ranks against established alternatives.

The appointment, recovery, and next steps

The procedure itself is a single outpatient appointment. ChondroFiller is prepared at the point of care and placed under real-time ultrasound guidance — no general anaesthetic, no hospital admission, no wound to manage afterward.

What follows that appointment requires patience and one firm practical constraint. A 2024 in vitro study confirmed that the collagen scaffold cannot protect opposing cartilage surfaces under full load in its initial state; the material needs time to integrate before the joint resumes normal mechanical demand. Post-injection weight-bearing restriction is not optional, and patients who understand the biomechanical reason for it tend to follow it more reliably than those who receive it as instruction alone. Dosing precision at the time of injection matters equally: the 2025 wrist RCT confirmed that flush application — placing the material level with surrounding cartilage rather than overfilling — prevents fibrous tissue formation associated with excess material. Ultrasound guidance enables that calibration in real time.

Symptom improvement is not immediate. Clinical studies show benefit emerging progressively over the first three to six months, with functional scores continuing to improve before plateauing between six and twelve months — a trajectory that reflects the biology of cellular recruitment and surface stabilisation rather than a simple analgesic effect.

The evidence as a whole makes one argument about timing: ChondroFiller performs best when joint architecture remains intact and damage has not yet compressed the joint space — precisely the scenario that inside-knee pain without swelling represents. Specialist assessment, including advanced MRI staging, is what establishes whether that window is still open. Appointments for assessment at London Cartilage Clinic can be arranged at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing for focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
5. [5] Implantation of ChondroFiller Liquid as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z